Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Apply for the ASN Home Dialysis Scholarship 2025-6 Program by May 31, 2025 Posted 05-20-2025
- Vantive is Supporting ASN’s Centers of Excellence in Home Dialysis Program Posted 05-20-2025
- NKF Spring Clinical Meeting Home Dialysis Posters Posted 04-23-2025
- Visit the MEI Booth (#100) at the Upcoming ANNA National Symposium Posted 04-23-2025